Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

    ... t(3;3) t(6;9) t(9;22) Normal karyotype with FLT3-ITD mutation Chronic myelogenous leukemia (accelerated, blast or ...

    Clinical Trial last updated 05/09/2016 - 3:58pm.

  2. Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

    ... hematologic malignancies that harbor an IDH1 and/or IDH2 mutation Status:  ...

    Clinical Trial last updated 04/28/2016 - 10:59am.

  3. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

    Journal Title:  Nat Commun. Primary Author:  Gerstung M Author(s):  Gerstung ...

    Research Article last updated 03/02/2015 - 1:43pm.

  4. Intra-Osseous Co-Transplant of UCB and hMSC

    ... markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation , 11q23, del 5, del 7, complex cytogenetics) Second complete ...

    Clinical Trial last updated 05/02/2016 - 11:15am.

  5. Dr. Vivienne Rebel reports on a study of the relationship between gene mutations and overall survival after stem cell transplant

    ... survival after transplantation for patients with this mutation was only 4.6 months and none lived much beyond 4 years.  Thus, it ... has minimal, if any, benefits for MDS patients with a TP53 mutation.  The authors conclude that if a blood-stem cell transplantation is ...

    Research Review last updated 05/02/2016 - 9:16am.

  6. Identification of genetic abnormalities in MDS patients that may lead to a better diagnosis and treatment strategy of MDS patients

    ... (nearly twice as high) in the group of patients with a mutation in the TET2 gene in their blood cells compared to the group who did not have this mutation.  Mutations that can predict therapeutic outcome are of importance ...

    Research Review last updated 05/02/2016 - 9:23am.

  7. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... (14%) genes.   In Cohort 2, 37% of patients had a mutation in a splicing factor gene ( SF3B1 , U2AF1 , SRSF2 , or ... of patients in Cohort 2 than Cohort 1 had a genetic mutation associated with a poor prognosis (especially TP53 ). Also, fewer ...

    Research Review last updated 05/02/2016 - 9:26am.

  8. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... that 78% of MDS patients carry at least one somatic mutation .  Knowledge of these mutations may help in diagnosing patients as ...

    Research Review last updated 05/02/2016 - 9:14am.

  9. Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    ... abnormalities); or Acute myeloid leukemia with Flt-3 mutation in complete hematologic remission; or Acute myeloid leukemia, ...

    Clinical Trial last updated 05/02/2016 - 11:10am.

  10. Immune System Suppression and Bone Marrow Failure

    ... DNMT3A  and  ASXL1 and another had a RUNX1 mutation . Telomeres were very short in all of the patients with monosomy 7. ...

    Research Review last updated 05/02/2016 - 9:15am.